The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Dyslipidemia contributes to endothelial dysfunction in type 2 diabetes mellitus. Fenofibrate (FF), a ligand of the peroxisome proliferator-activated receptor-α (PPARα), has beneficial effects on microvascular complications. FF may act on the endothelium by regulating vasoactive factors, including endothelin-1 (ET-1). In vitro, FF decreases ET-1 expression in human microvascular endothelial cells. We investigated the molecular mechanisms involved in the effect of FF treatment on plasma levels of ET-1 in type 2 diabetes mellitus patients. Methods and Results-FF impaired the capacity of transforming growth factor-β to induce ET-1 gene expression. PPARα activation by FF increased expression of the transcriptional repressor Krüppel-like factor 11 and its binding to the ET-1 gene promoter. Knockdown of Krüppel-like factor 11 expression potentiated basal and transforming growth factor-βstimulated ET-1 expression, suggesting that Krüppel-like factor 11 downregulates ET-1 expression. FF, in a PPARαindependent manner, and insulin enhanced glycogen synthase kinase-3β phosphorylation thus reducing glycogen synthase kinase-3 activity that contributes to the FF-mediated reduction of ET-1 gene expression. In type 2 diabetes mellitus, improvement of flow-mediated dilatation of the brachial artery by FF was associated with a decrease in plasma ET-1. Conclusion-FF decreases ET-1 expression by a PPARα-dependent mechanism, via transcriptional induction of the Krüppel-like factor 11 repressor and by PPARα-independent actions via inhibition of glycogen synthase kinase-3 activity. (Arterioscler Thromb Vasc Biol. 2013;33:621-628.)
D yslipidemia contributes to endothelial dysfunction in type 2 diabetes mellitus (T2D) 1 and involves vasoactive peptides, such as endothelin-1 (ET-1). 2 Clinical trials suggest fenofibrate (FF) improves microvascular complications of T2D. [3] [4] [5] FF is a ligand of the peroxisome proliferator-activated receptor-α (PPARα), which on heterodimerization with the Retinoid X Receptor binds to peroxisome proliferator response elements (PPRE) in target gene promoters and activates the transcription of genes, hence improving diabetic dyslipidemia. 6, 7 FF also displays pleiotropic nonlipid effects thus reducing fibrinogen, C-reactive protein, and uric acid levels and the expression of adhesion molecules, tissue factor, interleukin-6, COX-2, and ET-1 6, 8 and also improving flow-mediated dilatation via an increase in endothelial nitric oxide synthase expression and activity. 9, 10 In macrovascular endothelial cells (ECs), PPARα activation inhibits signaling pathways, such as activator protein (AP)-1 and nuclear factor-κB, thus collectively decreasing vascular inflammation. 11 ET-1 is a potent vasoconstrictor expressed both in microvascular and in macrovascular ECs. Plasma ET-1 levels are elevated in patients with diabetes mellitus. 12 Genetic factors relate to diabetic microvascular complications and association of the transforming growth factor-β (TGFβ) T869C gene polymorphism with an increased risk of nephropathy and retinopathy in T2D has been observed. 13 The ET-1 promoter has binding sites for AP-1 and Smad transcription factors, which functionally cooperate through cAMP-response element binding protein/p300 to mediate TGFβ-induced transcriptional activation of the ET-1 gene. 14 TGFβ binding to its transmembrane receptor kinases initiates intracellular signaling cascades, including Smad-dependent 15 and also Smad-independent pathways. 16 Studies on Smad-independent gene expression have identified a novel family of TGFβ-inducible Sp1/Krüppel-like factors (KLF)-like transcription factors contributing to the effects of TGFβ on cell growth and differentiation. 17 KLF11 is a member of this family, which mediates TGFβ-induced actions, for example, the repression of c-myc by TGFβ in epithelial cells. Mechanistically, KLF11 accomplishes this function by promoter binding via specific GC-rich sites and recruiting the Sin3histone deacetylase chromatin remodeling complex. 18 Glycogen synthase kinase-3 (GSK3) is a widely expressed and highly conserved serine/threonine protein kinase, which controls TGFβ signaling. 19 Thus, GSK3 mediates TGFβinduced phosphorylation of Smad3 at the linker region. 20 GSK3 is different from other kinases because it is generally highly active in resting cells, but inhibited in response to cellular signals, 21 including signals activating receptor tyrosine kinases that activate the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. 22 PPARα agonists improve microvascular complications of T2D, 4 in part, owing to actions on the endothelium. We previously showed that FF improved endothelial function in diabetic patients. 23 We now investigate the molecular mechanisms by which FF regulates ET-1 expression and the effect of FF on plasma ET-1 levels in T2D patients.
Materials and Methods
The immortalized human microvascular EC line (HMEC-1) was a generous gift of F.J. Candal (Atlanta, GA). 24 The KLF11 expression vector was a gift from R. Urrutia (Rochester, MN).
RNA Analysis
HMEC-1 cells were incubated with vehicle or FF (100 μmol/L) in MCDB131 medium containing 0.2% fetal calf serum, with or without TGFβ (10 ng/mmol/L), GSK3 inhibitor IX (50 nmol/L), Kenpaullone (2.3 μmol/L), Wortmannin (1 μmol/L), or insulin (100 nmol/L). For RNA quantification, see Methods in the online-only Data Supplement.
KLF11-Luc Promoter Constructs
A 2-kb KLF11 promoter region (−1910/+144) was amplified from genomic DNA as described in Methods in the onlineonly Data Supplement.
Transfections
HMEC-1 cells were seeded at 40×10 3 cells/well in a 24-well plate and transfected with PromoFectin-HUVEC transfection reagent (Promocell GmbH) as described in Methods in the online-only Data Supplement.
Western Blot Analysis
Proteins were resolved by SDS-PAGE electrophoresis followed by western blotting using specific antibodies (antiphospho-GSK-3α/β[Ser-21/9] [Cell Signaling Technology, Ozyme], goat polyclonal antibody anti-KLF11:sc-23162 [Santa Cruz, TEBU-Bio], and monoclonal anti-β-actin:clone AC-15 [Sigma]) and the Immobilon Western HRP chemiluminescent substrate (Millipore).
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation experiments were performed as described in Methods in the online-only Data Supplement.
Statistical Analyses
Data are expressed as the mean±SEM, and differences analyzed for statistical significance by 1-way ANOVA or the Student t test (1-tailed).
Human Study
Thirty-five T2D subjects of similar age 23 were randomized, double-blind to treatment with FF 200 mg/d or placebo for 12 weeks. Plasma ET-1 was measured at baseline and after treatment using a high-sensitivity radioimmunoassay (Biotrak RPA 545, Amersham Biosciences, UK). Treatment effects (FF and placebo) on plasma ET-1 levels were analyzed using paired t test (within treatment group) and the Mann-Whitney U test (between treatment groups).
Results

FF Decreases ET-1 mRNA While Increasing KLF11 Expression in HMEC-1 Cells
We previously showed that PPARα activators downregulate human ET-1 promoter activity by reducing AP-1 DNA-binding activity after thrombin stimulation. 25 Because ET-1 expression is also TGFβ-regulated, 14 we evaluated the effect of FF treatment on TGFβ induction of ET-1 in HMEC-1 cells ( Figure  1A and 1B). FF inhibited the TGFβ-mediated increase in ET-1 expression in a dose-and time-dependent manner, an effect most pronounced at 100 μmol/L of FF and already observed within 8 hours of treatment. The effects of FF on ET-1 mRNA expression were accompanied by similar changes in ET-1 secretion in the cell culture medium ( Figure 1A ). Because a transcriptional repressor could be involved in this action of FF, because KLF transcription factors are involved in cardiovascular diseases 26 and mediate TGFβ-induced actions, and because recent transcriptomic analysis proposed KLF11 as a PPARα-regulated gene in human hepatocytes, 27 we measured KLF11 expression in HMEC-1 cells. FF treatment induced KLF11 mRNA ( Figure  1C ) already within 8 hours. Because KLF11 is a TGFβ-inducible early gene, 28 we also investigated the effect of TGFβ on KLF11 expression in confluent HMEC-1 cells treated or not with FF. Whereas FF potently increased KLF11 expression, no further increase occurred on cotreatment with TGFβ ( Figure 1C ). FF also increased KLF11 protein expression ( Figure 1D ).
FF-Activated PPARα Stimulates KLF11 Transcription via a PPRE in the KLF11 Promoter
Computer-assisted transcription factor mapping using Genomatix (http://www.genomatix.de/) identified a putative PPRE in the human KLF11 promoter at position −267/−244 ( Figure 2A ). To assess whether PPARα regulates KLF11 promoter activity, the upstream regulatory sequence (−1903/+153) of the human KLF11 gene was cloned in front of a luciferase reporter gene. FF strongly increased promoter activity in HMEC-1 cells transiently transfected with PPARα ( Figure 2B ). Since PPARα expression is low at the cell density required for optimal transient transfection (60%-80%), cotransfection of cells with a PPARα expression plasmid was required to evaluate the KLF11 promoter activation by PPARα ( Figure IA assay analysis using a radiolabeled oligonucleotide corresponding to the (−267/−244) KLF11 promoter sequence, containing the PPRE, showed binding of the PPARα/Retinoid X Receptor heterodimer to the probe which is competed by cold wild-type, but not mutated PPRE oligonucleotide ( Figure 2D ). Finally, chromatin immunoprecipitation assays showed PPARα binding to the KLF11 promoter increased by FF treatment (Figure 2E ).
FF Increases KLF11 Binding to the ET-1 Promoter, Which Contributes to the Reduction of Basal and TGFβ-Induced ET-1 Expression in HMEC-1 Cells
To test whether PPARα induction of KLF11 accounts for the effect of FF on ET-1 expression, we investigated whether KLF11 binds to the ET-1 promoter in cell. In silico analysis identified potential KLF11 binding sites in the −650bp region of the ET-1 promoter ( Figure 3A) . Chromatin immunoprecipitation assays using primer pairs covering these putative KLF binding sites showed specific binding of KLF11 on the ET-1 promoter in confluent HMEC-1 cells, which was increased by FF ( Figure 3A ). siRNA knockdown of KLF11 or PPARα expression to, respectively, 50% and 80% of control ( Figure 3C ) enhanced TGFβ-induced ET-1 mRNA expression, suggesting that both PPARα and KLF11 exert inhibitory actions on TGFβ-induced ET-1 expression ( Figure 3B ).
The PI3K/Akt/GSK3 Pathway Is Involved in the ET-1 mRNA Decrease by FF
Surprisingly, TGFβ-induced ET-1 expression was still reduced by FF, albeit to a lesser extent, on siRNA knockdown of PPARα, suggesting PPARα-independent mechanisms ( Figure 4A ). Because the PI3K/Akt/GSK3 pathway also mediates TGFβ signaling, 16 we analyzed the effect of FF on GSK3β phosphorylation in HMEC-1 cells. FF increased the inactivating Ser-9 phosphorylation of GSK3β ( Figure 4B ). The induction of GSK3β phosphorylation was observed early and remained elevated for 24 hours, suggesting that FF-induced GSK3 phosphorylation could contribute to the regulation of ET-1 expression. To confirm the implication of the GSK3 pathway in the decrease of ET-1 mRNA expression by FF, different GSK3 inhibitors were tested on confluent HMEC-1 cells. Treatment for 24 hours with the GSK3 inhibitors IX and Kenpaullone decreased ET-1, but not KLF11 mRNA expression ( Figure 4C and  4D) . These results suggest that FF-mediated reduction in GSK3 activity contributes to the decrease of ET-1 mRNA levels in a KLF11-independent way. Because insulin receptor activation in the endothelium induces the PI3K/Akt pathway and vasodilatation, 29 we investigated also the effect of insulin on ET-1 expression. Insulin decreased ET-1 expression in HMEC-1 cells ( Figure 4E) , an effect reverted by wortmannin, an inhibitor of Akt. Moreover, insulin strongly increased the inhibitory phosphorylation of GSK3, which was reduced by treatment with wortmannin ( Figure 4F ). Moreover, wortmannin treatment increased ET-1 expression in line with a role of Akt/GSK3 pathway in ET-1 regulation, even on KLF11 knockdown ( Figure 4G ). On KLF11 knockdown, FF still inhibited the wortmannin-mediated increase of ET-1 expression, suggesting that FF acts downstream of Akt.
FF Decreases Plasma ET-1 in T2D Patients
T2D subjects have impaired endothelial function that improves with FF as measured by brachial artery flow-mediated dilatation. Evaluation of the effects of FF on plasma ET-1 levels by ELISA assay ( Figure 5A ) showed a significant ontreatment decrease in plasma ET-1 (P=0.032; baseline versus end), whereas there was no significant on-treatment change in the placebo group (P=0.415). FF treatment decreased plasma ET-1 significantly compared with placebo (P=0.010).
Discussion
Our previous studies 23 showed that FF improves macro-and microcirculatory function. We now investigated the molecular mechanisms underlying the beneficial effect of FF on microcirculation in diabetes mellitus by studying ET-1 regulation. In human microvascular endothelial HMEC-1 cells, FF significantly decreased ET-1 mRNA, an effect most pronounced on TGFβ activation. We thus hypothesized that a transcriptional repressor accounts for this action of FF. KLF11 has been recently identified by Affymetrix GeneChip analysis as a PPARα-induced gene in mouse and human hepatocytes. 27 We show that KLF11 is a bona fide PPARα target gene in human ECs. KLF11 induction by FF occurs at the transcriptional level via a PPRE located near its transcription start site. KLF11 regulates ET-1 because reduction of endogenous KLF11 by siRNA increased ET-1 expression. We further identified KLF11 binding sites within the ET-1 gene. FF increased KLF11 occupancy on the ET-1 promoter. Therefore, we identify a novel molecular pathway regulating ET-1 expression through PPARα-mediated induction of the . Fenofibrate (FF) increases glycogen synthase kinase-3β (GSK3β) phosphorylation that contributes to a PPARα-independent reduction of endothelin-1 (ET-1) expression. A, Human microvascular endothelial cell line-1 (HMEC-1) cells transfected with PPARα-or ctrl-siRNA and treated with transforming growth factor-β (TGFβ) and FF. ET-1 mRNA expression was analyzed by quantitative polymerase chain reaction (qPCR) and normalized to cyclophilin mRNA. Statistical differences were calculated using unpaired t test (1-tailed; vehicle vs FF: P<0.0001 for sictrl and vehicle vs FF: P=0.0015 for short interfering [si]PPARα). B, Confluent HMEC-1 cells were treated with vehicle or FF. Total cell lysates were then analyzed for expression of GSK3β and Ser-9 phosphorylation of GSK3β by immunoblotting. GSK3β phosphorylation intensities of the western blot bands normalized to GSK3β measured using the ImageQuant software are indicated. C and D, Confluent HMEC-1 cells were treated with vehicle, FF, GSK3 inhibitor IX (IX), Kenpaullone (K). ET-1 (C) or KLF11 (D) mRNA were measured by qPCR and normalized to cyclophilin mRNA (mean±SEM of triplicate determinations). Statistical differences were calculated using unpaired t test (1-tailed; vehicle vs FF: P=0.0012; vehicle vs inhibitor IX: P=0.0035; vehicle vs Kenpaullone: P=0.0007 for ET-1 and vehicle vs FF: P=0.017 for KLF11). E, Confluent HMEC-1 cells were treated with vehicle, insulin (Ins), or Ins+wortmannin (Wrt). Cells were analyzed for ET-1 mRNA expression normalized to cyclophilin mRNA (mean±SEM of triplicate determinations). Statistical differences were calculated using unpaired t test (1-tailed; vehicle vs Ins: P=0.0003; Ins vs Ins+Wrt: P=0.0087). F, Confluent HMEC-1 cells treated with vehicle, FF, FF+Wrt, Ins or Ins+Wrt and GSK3 protein measured by western blotting using GSK3β and phosphorylated GSK3β antibodies. G, HMEC-1 cells were transfected with KLF11-or ctrl-siRNA, treated with FF and Wrt and TGFβ. ET-1 mRNA expression was analyzed by qPCR normalized to cyclophilin mRNA. Statistical differences were calculated using 1-way ANOVA followed by Newman-Keuls-corrected post hoc analysis (Wrt vs Wrt+FF: P<0.001 for siKLF11).
repressor KLF11. ET-1 expression is regulated by numerous factors, among which TGFβ seems most important. 30 FF also repressed TGFβ-induced ET-1 gene expression in a PPARαand KLF11-dependent manner. We previously described that TGFβ induces ET-1 gene expression through functional cooperation between Smad proteins and AP-1 transcription factors at specific binding sites within the proximal ET-1 promoter. 14 The present study identified, in the ET-1 gene, putative KLF11 binding sites in the proximity of Smad and AP-1 sites. Therefore, KLF11 may repress basal and TGFβstimulated ET-1 expression by interfering with Smad and AP-1 transcription factors.
However, the transcriptional activation of KLF11 expression by FF does not account for the whole effect of FF on ET-1 expression as siRNA-mediated PPARα silencing did not completely prevent the effect of FF on TGFβ-induced ET-1 expression. Therefore, we examined the effects of FF on the PI3K/Akt-GSK3 pathway as it is involved in TGFβ signaling. 16 FF increased the Ser-9 phosphorylation of GSK3β in HMEC-1 cells, which results in GSK3β inhibition. By contrast, the TCF7L2 transcription factor, a canonical Wnt/β-catenin downstream effector, is not involved in the FF-mediated reduction of ET-1 expression ( Figure II in the online-only Data Supplement). Smad3 activity increases on treatment with FF or GSK3 inhibitors ( Figure III in the onlineonly Data Supplement) but its exact role on FF regulation of the ET-1 promoter remains to be determined. Wortmannin, which inhibits insulin-activation of Akt, 31 induced ET-1 especially on KLF11 knockdown. However, on KLF11 expression reduction, FF still inhibited ET-1-induction by wortmannin illustrating the existence of mechanisms different from KLF11 and downstream the Akt pathway. In line, potential roles of nuclear factor-κB and AP-1 in the effect of FF on ET-1 expression were identified in macrovascular ECs and cardiomyocytes. 11, 25, 32, 33 ET-1 expression is also inhibited by insulin, via activation of the Akt/GSK3 pathway suggesting that FF mimics the effect of insulin. In T2D patients, FF treatment was associated with a decrease in plasma ET-1 levels, most relevantly in those whose ET-1 levels were significantly elevated compared with nondiabetic controls (data not shown). Despite random allocation of subjects to treatment groups, the lower plasma ET-1 levels in the placebo group could be owing to sampling variation, and may account for why the between-group changes were less significant after adjustment for baseline values. Nevertheless, these observations provide a partial explanation for our finding that FF improves resistance vessel function and ambulatory blood pressure in diabetes mellitus 34, 35 and could provide a contributing mechanism explaining the beneficial effects of FF on microvascular complications of diabetes mellitus in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Type 2 Diabetes (ACCORD) trials, including a significant reduction in the need for laser treatment of retinopathy, as well as a delay in the progression of nephropathy. [36] [37] [38] There is also a significant reduction in the risk of minor amputations in the absence of large-vessel disease, as observed in the FIELD study. 39 Our study supports the hypothesis that the beneficial effects of FF treatment in T2D patients on microvascular circulation may be, in part, mediated by decreased ET-1 levels. FF acts by counteracting effects of TGFβ, which is increased in T2D 40 by decreasing AP-1 binding on the ET-1 promoter ( Figure IV in the online-only Data Supplement) and GSK3 activity ( Figure V in the online-only Data Supplement). TGFβ elevation has been linked to diabetic complications, particularly to nephropathy, retinopathy, and cardiovascular diseases. 41, 42 In conclusion, we propose a novel molecular mechanism whereby FF may improve the microcirculatory dysfunction in T2D ( Figure 5B ). FF significantly decreases ET-1 expression by a PPARα-dependent mechanism, via the transcriptional activation of the KLF11 repressor, and by PPARα-independent actions via the inhibition of GSK3 activity. 
